VIRALEZE nasal spray. Source: Starpharma
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Starpharma (SPL) registers its nasal spray product VIRALEZE in Indonesia after gaining marketing authorisation
  • The company says Indonesia represents an “exciting market opportunity” as its the largest and most populated country in Southeast Asia, and it’s now in discussions with potential distribution partners
  • The VIRALEZE nasal spray is now registered in more than 30 countries and is available in pharmacies, retail outlets and online in certain markets
  • Starpharma is also continuing to progress regulatory and commercial activities in multiple other countries
  • Shares in Starpharma are up 2.86 per cent, trading at 54 cents at 1:53 pm AEDT

Starpharma (SPL) has registered its nasal spray product VIRALEZE in Indonesia after gaining marketing authorisation.

Following the successful registration, the company is in discussions with potential distribution partners in Indonesia.

CEO Jackie Fairley said Indonesia represents an “exciting market opportunity” for the company as the country is the largest and most populous country in Southeast Asia.

“We have seen strong interest in VIRALEZE across Asia, including in Vietnam, and in Hong Kong and Macau where the product recently launched through major pharmacy chains, Mannings and Watsons, as well as selected supermarkets.”

The VIRALEZE nasal spray is now registered in more than 30 countries and is available in pharmacies, retail outlets and online in certain markets.

Starpharma is also continuing to progress regulatory and commercial activities in multiple other countries, including in markets across Southeast Asia.

VIRALEZE is a nasal spray that is intended to physically trap, and block cold and respiratory viruses in the nasal cavity.

Multiple nonclinical studies have shown that VIRALEZE traps and blocks a broad spectrum of respiratory viruses, including human coronaviruses, influenza viruses, rhinoviruses, and respiratory syncytial virus.

Shares in Starpharma were up 2.86 per cent, trading at 54 cents at 1:53 pm AEDT.

SPL by the numbers
More From The Market Online
The Market Online Video

Market Close: ASX Ltd drops on ASIC $150M raise request; iron ore offsets gold bounceback

Good Afternoon and welcome to Market Close for Monday of Week 51, I’m Jon Davidson.
HotCopper Daily Market Trends Graphic

Monday’s HotCopper trends: Winsome, 4D Medical, and other daily topics | Dec 15

With more than seven million users on the HotCopper forums, every discussion and speculation can move Australian markets, which is why getting out in front
A dirt road running through the Antimony Canyon project in Utah.

American Tungsten and Antimony leaves ‘Trigg’ name behind to start next era (and set fresh focus)

American Tungsten and Antimony has entered a new era, leaving the name "Trigg Minerals" behind to…
The Market Online Video

How to manage money on the average Aussie income

This week on Money and Investing, Mitch Olarenshaw and I break down how to manage money on the average Australian income, using practical